Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28182194 | 1.00 | KDM4E (0.54) | KDM4EEPHX2LMNACYP3A4GABRA1 | |
| Hydrochloric Acid SCHEMBL2250330 | 0.98 | KDM4E (0.52) | KDM4EEPHX2LMNACYP3A4GABRA1 | |
| SCHEMBL25176113 | 0.98 | KDM4E (0.50) | KDM4EEPHX2LMNACYP3A4GABRA1 | |
| Hydrochloric Acid SCHEMBL2588089 | 0.96 | KDM4E (0.48) | KDM4EEPHX2LMNACYP3A4GABRA1 | |
| SCHEMBL9936711 | 0.89 | KDM4E (0.48) | KDM4EEPHX2LMNACYP3A4GABRA1 | |
| SCHEMBL1161139 | 0.89 | KDM4E (0.48) | KDM4EEPHX2LMNACYP3A4GABRA1 | |
| Hydrochloric Acid SCHEMBL189808 | 0.86 | KDM4E (0.46) | KDM4EEPHX2LMNACYP3A4GABRA1 | |
| SCHEMBL20507730 | 0.85 | KDM4E (0.52) | KDM4EEPHX2LMNACYP3A4GABRA1 | |
| SCHEMBL7130917 | 0.84 | EPHX2 (0.53) | EPHX2LMNATSHRCHRM4CA2 | |
| Hydrochloric Acid SCHEMBL13386352 | 0.83 | KDM4E (0.50) | KDM4EEPHX2LMNACYP3A4GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442533-B1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | UNIV OTTAWA (CA) | 2024-08-07 | — | — | EP | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-10894777-B2 | TG2 inhibitor piperazine compounds and uses thereof | UNIVERSITY OF OTTAWA (CA) | 2021-01-19 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| EP-3599236-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3202460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-3106460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3442533-A1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | University Of Ottawa (CA) | 2019-02-20 | — | — | EP | disclosed |
| EP-3202461-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2018-12-26 | — | — | EP | disclosed |
| CN-104693193-B | Aryl methoxy isoindoline derivative and composition and their application method including it | 细胞基因公司 | 2018-09-18 | — | — | CN | disclosed |
| US-20180037567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-02-08 | — | — | US | disclosed |
| WO-2017179018-A1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2017-10-19 | — | — | WO | disclosed |
| EP-3202461-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3202460-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2536706-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3106460-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | KDM4E 2260/4885EPHX2 1557/4885LMNA 2785/4885 |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | KDM4E 2260/4885EPHX2 1557/4885LMNA 2785/4885 |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | KDM4E 2260/4885EPHX2 1557/4885LMNA 2785/4885 |
| US-10894777-B2 | TG2 inhibitor piperazine compounds and uses thereof | TGM2, TGM1, TGM3 | KDM4E 1339/4885EPHX2 2526/4885LMNA 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.